^
Association details:
| Biomarker: | EGFR mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Tagrisso (osimertinib) (EGFR inhibitor) + Orpathys (savolitinib) (c-MET inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC
Excerpt:
...- Histologically or cytologically confirmed locally advanced or metastatic EGFRm+ NSCLC harbouring an EGFR mutation known to be associated with EGFR TKI sensitivity and that is permitted in the osimertinib national label (such as exon 19 deletion and/or L858R), which is...
Trial ID:
Source:
Title:
Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment
Excerpt:
...EGFR mutation:...
Trial ID:
More C2 evidence
Source:
Title:
Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib
Excerpt:
...- Histologically or cytologically confirmed locally advanced or metastatic EGFRm+ NSCLC harbouring an EGFR mutation known to be associated with EGFR TKI sensitivity and permitted in the osimertinib national label (such as either exon 19 deletion and/or L858R) which is...
Trial ID:
Source:
Title:
Osimertinib With or Without Savolitinib as 1L in de Novo MET+, EGFR+ NSCLC
Excerpt:
...Histologically or cytologically confirmed locally advanced or metastatic EGFRm+ NSCLC harbouring an EGFR mutation known to be associated with EGFR TKI sensitivity....
Trial ID:
Source:
Title:
A clinical trial to compare the effectiveness of savolitinib plus osimertinib versus chemotherapy for the treatment of non-small cell lung cancer Un ensayo clínico para comparar la eficacia de savolitinib más osimertinib frente a la quimioterapia para el tratamiento del cáncer de pulmón no microcítico
Excerpt:
...- Must have at least one documented sensitising EGFR mutation: exon19 deletion, L858R mutation, and/or T790M. ...
Trial ID:
Source:
Title:
Osimertinib plus savolitinib in patients with EGFRm+/MET+ non small cell lung cancer following prior osimertinib
Excerpt:
...All genders are permitted.- Histologically or cytologically confirmed locally advanced or metastatic EGFRm+ NSCLC harbouring an EGFR mutation known to be associated with EGFR TKI sensitivity and permitted in the osimertinib national label (such as either exon 19 deletion and/or L858R) which is not amenable to curative therapy.- Documented radiologic disease progression on first line osimertinib.- MET-amplification and/or overexpression (FISH10+ and/or IHC90+) as determined by FISH (central) and IHC (central) testing on tumour sample collected following progression on 1L osimertinib treatment.- Available tumour sample for central MET FISH and IHC analysis or willingness to collect additional tissue for central testing which fulfils the following requirements: Obtained following progression on previous osimertinib therapy; obtained within 2 years of submission for MET analysis; sufficient tissue to meet the minimum tissue requirement defined in the current Laboratory Manual. ...
Trial ID:
Less C2 evidence
Source:
Title:
387P - Phase Ib study of savolitinib ± osimertinib in Japanese patients (pts) with advanced solid malignancies & EGFRm NSCLC: TATTON part C
Published date:
11/17/2020
Excerpt:
Pts receiving the combination (across doses) had an objective response rate of 42% (95% confidence interval 15.2, 72.3). Preliminary data demonstrate an acceptable safety profile for savolitinib and suggest antitumor activity in combination with osimertinib in Japanese pts with EGFRm NSCLC.
Trial ID:
Source:
Title:
TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer
Published date:
01/24/2020
Excerpt:
Patients with advanced EGFR-mutant non-small-cell lung cancer and disease progression on a prior EGFR-TKI were enrolled...The objective response rate was 42% (95% confidence interval 26% to 59%), 44% (22% to 69%), and 43% (23% to 66%) in the selumetinib, savolitinib, and durvalumab arms, respectively....results demonstrate the feasibility of combining osimertinib 80 mg with selumetinib or savolitinib at identified tolerable, active doses.
DOI:
https://doi.org/10.1016/j.annonc.2020.01.013
Trial ID:
Source:
Title:
Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer
Excerpt:
Here, we present a case of a patient with lung adenocarcinoma harboring both a mutation in EGFR and an amplification of MET, who after progression on erlotinib responded dramatically to combined MET and EGFR inhibition with savolitinib and osimertinib.
DOI:
10.1158/2159-8290.CD-16-0686
